Emory team to look at GSK vax response as part of NIH research

After a GlaxoSmithKline herpes zoster subunit vaccine posted 97% efficacy in all age groups in a recent Phase III trial, a research team will look further into how the vaccine was able to immunize the elderly, who are typically tougher to vaccinate due to weaker immune responses.

J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine

Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.

UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target

Researchers at the University of California, Berkeley, have identified a viral protein that causes fluid loss and shock that indicate severe and potentially fatal dengue infections.

With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs

The CDC's Advisory Committee on Immunization Practices has stopped short of recommending routine meningitis B immunization, leaving the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.

Agenus trades adjuvant rights to GSK for $115M to bolster oncology profile

Immunotherapy developer Agenus, looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline to grab $115 million in exchange for royalties it once held on an adjuvant for GSK's malaria and shingles vaccines.

Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs

Older adults don't have as robust an immune response to the flu vaccine as young people do. So Sanofi Pasteur formulated a higher-dose version of its trivalent Fluzone vaccine, which was found in an economic analysis to result in lower medical costs for older adults.

VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine

Canada's National Research Council-Industrial Research Assistance Program has awarded VBI Vaccines up to CA$350,000 ($265,000) to apply VBI's viruslike particle technology in the development of an RSV vaccine, the company announced on Tuesday.

Merck's Zostavax not cost-effective for those in their 50s: Study

The CDC doesn't currently recommend Merck's shingles vaccine, Zostavax, for those between the ages of 50 and 60. And a new analysis of the vaccine's cost-effectiveness in that population suggests it should stay that way.

Cornell grad looks to change the way parents remember vaccine schedules

While spending a summer in Peru after her sophomore year at Cornell University, Lauren Braun came up with an idea that could change the way parents in developing countries around the world remember their children's vaccination needs.

NHS meningitis B vaccination scheme begins in U.K.

The British Joint Committee on Vaccination and Immunisation recommended that a meningitis B jab be added to the routine childhood vaccination schedule. But thanks to pricing negotiations, the administration of GlaxoSmithKline's--formerly Novartis'--Bexsero to babies aged two months, four months and 12-13 months began just this week.

GlaxoSmithKline signs on LimmaTech for vaccine R&D

When GlaxoSmithKline bought out GlycoVaxyn for $190 million early this year, it gained a set of early-stage vaccines and commissioned GlycoVaxyn's team to create a new company around its existing research operation. That company is LimmaTech Biologics, which announced the start of its operations on Friday.

Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan

Just in time for flu season, AstraZeneca granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan. The live attenuated vaccine, delivered nasally, went through Phase III trials in Japanese children, and a regulatory submission is being prepared for Japan.

BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII

Last week saw two developments by players large and small in a universal flu vaccine race that's heating up. Now, Israel-based BiondVax is following up with some news of its own: It's partnering with the National Institute of Allergy and Infectious Diseases to test its candidate in the U.S.

Looking to Opdivo combo trial, Heat ends cancer vaccine PhII

Cancer vaccine/checkpoint inhibitor partnerships just keep rolling in. On Tuesday, oncology company Heat Biologics announced that it's the most recent to get involved, though it'll be applying the method to a cancer that so far others haven't.

Takeda expands vaccine platform rights with Nanotherapeutics agreement

In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.

Valneva licenses EB66 technology to develop human, veterinary vaccines

Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.

Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials

Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and national unease about the infection spreading on college campuses. Now, the New York-based pharma announced positive late-stage results on Friday in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.

Mathematical models show one dose of Shanchol may be sufficient during epidemics

Shanchol, the cholera vaccine used in endemic countries, is given in two doses 6 weeks apart. But some patients may simply not return for a second dose. If the second dose is delayed by more than 6 weeks, the WHO says, the whole regimen has to be restarted.

FluGen reels in $12M to fund PhI of its universal flu jab

A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.

J&J, Scripps Research Institute test 'universal' flu vaccine in mice, monkeys

The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.